Inoviq Ltd

IIQ

Company Profile

  • Business description

    Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.

  • Contact

    23 Normanby Road
    Notting Hill
    MelbourneVIC3168
    AUS

    T: +61 395487586

    http://www.inoviq.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    30 June 2026

    Employees

    5

Stocks News & Analysis

stocks

Is this ASX share a value trap or bargain?

Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks

Goldman Sachs Earnings: Valuations remain stretched

We raise our fair value estimate for Goldman Sachs stock.
stocks

Major ASX listed miners overvalued

We’ve adjusted our fair values after updating our commodity price assumptions.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,138.6019.70-0.22%
CAC 408,038.2773.75-0.91%
DAX 4024,658.34300.72-1.20%
Dow JONES (US)49,359.3383.11-0.17%
FTSE 10010,097.7697.59-0.96%
HKSE26,487.5176.39-0.29%
NASDAQ23,515.3914.63-0.06%
Nikkei 22552,991.10592.47-1.11%
NZX 50 Index13,573.936.36-0.05%
S&P 5006,940.010.000.00%
S&P/ASX 2008,815.9020.70-0.23%
SSE Composite Index4,113.650.35-0.01%

Market Movers